APA (7th ed.) Citation

L, W., SC, S., FJ, G., NS, S., MG, P., SP, R., . . . J, C. (2026). PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy. European journal of nuclear medicine and molecular imaging, 53(7), 4360. https://doi.org/10.1007/s00259-026-07788-4

Chicago Style (17th ed.) Citation

L, Widjaja, et al. "PET-based Risk Stratification for Adverse Events Under [225Ac]Ac-PSMA Radioligand Therapy." European Journal of Nuclear Medicine and Molecular Imaging 53, no. 7 (2026): 4360. https://doi.org/10.1007/s00259-026-07788-4.

MLA (9th ed.) Citation

L, Widjaja, et al. "PET-based Risk Stratification for Adverse Events Under [225Ac]Ac-PSMA Radioligand Therapy." European Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 7, 2026, p. 4360, https://doi.org/10.1007/s00259-026-07788-4.